Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its Q1 fiscal year 2024 financial results on November 14, 2023, before market open. A conference call and webcast to discuss the results, business strategy, partnerships, and regulatory processes will follow at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
11/07/2023 - 07:00 AM
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
Conference Call Details: To participate in the live conference call via telephone, please register here . Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.
Webcast Registration link: https://edge.media-server.com/mmc/p/mdyeh2j3
For further information, please contact:
Renalytix plc www.renalytix.com James McCullough, CEO Via Walbrook PR Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600 Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea Investec Bank plc (Joint Broker) Tel: 020 7597 4000 Gary Clarence / Shalin Bhamra Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com Paul McManus / Alice Woodings Mob: 07980 541 893 / 07407 804 654 CapComm Partners Peter DeNardo Tel: 415-389-6400 or investors@renalytix.com
About Renalytix Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com .
When will Renalytix plc report its financial results for Q1 fiscal year 2024?
Renalytix plc will report its Q1 fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open.
How can I participate in the conference call?
To participate in the live conference call via telephone, you can register at the provided link and upon registering, a dial-in number and unique PIN will be provided in order to join the conference call.
What topics will be discussed during the conference call?
The conference call will discuss the financial results, business strategy, partnerships, and regulatory and reimbursement processes.
How can I access the webcast?
You can access the webcast by registering at the provided link.
RNLX Rankings
#4481 Ranked by Stock Gains
RNLX Stock Data
Industry
Diagnostic Imaging Centers
Sector
Health Care and Social Assistance
Tags
Technology Services, Packaged Software, Health Care and Social Assistance, Diagnostic Imaging Centers
Country
United Kingdom
City
Penarth
About RNLX
renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. the company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. renalytixai’s initial diagnostic product, kidneyintelx™, is designed to diagnose and improve clinical management of patients with type ii diabetes and those of african ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the u.s. healthcare system. renalytixai expects to commercially launch kidneyintelx as a laboratory developed test in its clia laboratory facilities to health systems and drug developers in h2 2019. the company also intends to submit kidneyintelx for regulatory rev